The Jubilant Life Sciences stock has been declining in the first half of FY18 on the back of a muted business performance. A delay in contract manufacturing orders, pricing pressure in generics and integration of an acquisition impacted the company’s margins.
The stock has, however, witnessed a recovery since October on expectations of an improvement in growth outlook. The confidence on the company’s future prospects stems from improving outlook of its pharma segment (radio pharma products) and growing contract manufacturing (CMO) order book. The radio pharma ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Sat, December 30 2017. 01:54 IST
